Cargando…
Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy
BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374910/ https://www.ncbi.nlm.nih.gov/pubmed/30764790 http://dx.doi.org/10.1186/s12886-019-1063-8 |
_version_ | 1783395261937090560 |
---|---|
author | Herrera, Isabella Kam, Yong Whittaker, Thomas J. Champion, Mary Ajlan, Radwan S. |
author_facet | Herrera, Isabella Kam, Yong Whittaker, Thomas J. Champion, Mary Ajlan, Radwan S. |
author_sort | Herrera, Isabella |
collection | PubMed |
description | BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendronic acid infusion. She has a past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren’s syndrome, and systemic lupus erythematosus that have been controlled with immunosuppressive therapy for three years. Clinical ophthalmic exam and MRI studies were significant for right orbital inflammation. The patient was started on oral prednisone with rapid resolution of symptoms. CONCLUSIONS: This is the first case report of a patient receiving chronic immunosuppressive therapy to develop orbital inflammation after Zoledronic acid infusion. In addition, it demonstrates that corticosteroids can be an effective first line therapy in treating orbital inflammation in similar patients. Physicians should be aware of this rare but serious potential side effect of bisphosphonates, and have bisphosphonate-related orbital inflammation on their differential for proper initiation of treatment. |
format | Online Article Text |
id | pubmed-6374910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63749102019-02-26 Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy Herrera, Isabella Kam, Yong Whittaker, Thomas J. Champion, Mary Ajlan, Radwan S. BMC Ophthalmol Case Report BACKGROUND: To report a case of orbital inflammation after bisphosphonate infusion in a patient who was already receiving immunosuppressive therapy. CASE PRESENTATION: A 56-year-old woman presented to the ophthalmology clinic with acute onset of right eye pain 24 h after receiving her first Zolendronic acid infusion. She has a past medical history of chronic inflammatory demyelinating polyneuropathy, Sjogren’s syndrome, and systemic lupus erythematosus that have been controlled with immunosuppressive therapy for three years. Clinical ophthalmic exam and MRI studies were significant for right orbital inflammation. The patient was started on oral prednisone with rapid resolution of symptoms. CONCLUSIONS: This is the first case report of a patient receiving chronic immunosuppressive therapy to develop orbital inflammation after Zoledronic acid infusion. In addition, it demonstrates that corticosteroids can be an effective first line therapy in treating orbital inflammation in similar patients. Physicians should be aware of this rare but serious potential side effect of bisphosphonates, and have bisphosphonate-related orbital inflammation on their differential for proper initiation of treatment. BioMed Central 2019-02-14 /pmc/articles/PMC6374910/ /pubmed/30764790 http://dx.doi.org/10.1186/s12886-019-1063-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Herrera, Isabella Kam, Yong Whittaker, Thomas J. Champion, Mary Ajlan, Radwan S. Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title | Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title_full | Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title_fullStr | Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title_full_unstemmed | Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title_short | Bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
title_sort | bisphosphonate-induced orbital inflammation in a patient on chronic immunosuppressive therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374910/ https://www.ncbi.nlm.nih.gov/pubmed/30764790 http://dx.doi.org/10.1186/s12886-019-1063-8 |
work_keys_str_mv | AT herreraisabella bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy AT kamyong bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy AT whittakerthomasj bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy AT championmary bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy AT ajlanradwans bisphosphonateinducedorbitalinflammationinapatientonchronicimmunosuppressivetherapy |